Cargando…
High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709758/ https://www.ncbi.nlm.nih.gov/pubmed/28960192 http://dx.doi.org/10.1038/bcj.2017.96 |
| _version_ | 1783282837411069952 |
|---|---|
| author | Kusano, Y Yokoyama, M Terui, Y Inoue, N Takahashi, A Yamauchi, H Tsuyama, N Nishimura, N Mishima, Y Takeuchi, K Hatake, K |
| author_facet | Kusano, Y Yokoyama, M Terui, Y Inoue, N Takahashi, A Yamauchi, H Tsuyama, N Nishimura, N Mishima, Y Takeuchi, K Hatake, K |
| author_sort | Kusano, Y |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5709758 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-57097582017-12-04 High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy Kusano, Y Yokoyama, M Terui, Y Inoue, N Takahashi, A Yamauchi, H Tsuyama, N Nishimura, N Mishima, Y Takeuchi, K Hatake, K Blood Cancer J Letter to the Editor Nature Publishing Group 2017-09 2017-09-29 /pmc/articles/PMC5709758/ /pubmed/28960192 http://dx.doi.org/10.1038/bcj.2017.96 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| spellingShingle | Letter to the Editor Kusano, Y Yokoyama, M Terui, Y Inoue, N Takahashi, A Yamauchi, H Tsuyama, N Nishimura, N Mishima, Y Takeuchi, K Hatake, K High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy |
| title | High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy |
| title_full | High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy |
| title_fullStr | High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy |
| title_full_unstemmed | High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy |
| title_short | High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy |
| title_sort | high pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with r-chop-like therapy |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709758/ https://www.ncbi.nlm.nih.gov/pubmed/28960192 http://dx.doi.org/10.1038/bcj.2017.96 |
| work_keys_str_mv | AT kusanoy highpretreatmentlevelofsolubleinterleukin2receptorisarobustprognosticfactorinpatientswithfollicularlymphomatreatedwithrchopliketherapy AT yokoyamam highpretreatmentlevelofsolubleinterleukin2receptorisarobustprognosticfactorinpatientswithfollicularlymphomatreatedwithrchopliketherapy AT teruiy highpretreatmentlevelofsolubleinterleukin2receptorisarobustprognosticfactorinpatientswithfollicularlymphomatreatedwithrchopliketherapy AT inouen highpretreatmentlevelofsolubleinterleukin2receptorisarobustprognosticfactorinpatientswithfollicularlymphomatreatedwithrchopliketherapy AT takahashia highpretreatmentlevelofsolubleinterleukin2receptorisarobustprognosticfactorinpatientswithfollicularlymphomatreatedwithrchopliketherapy AT yamauchih highpretreatmentlevelofsolubleinterleukin2receptorisarobustprognosticfactorinpatientswithfollicularlymphomatreatedwithrchopliketherapy AT tsuyaman highpretreatmentlevelofsolubleinterleukin2receptorisarobustprognosticfactorinpatientswithfollicularlymphomatreatedwithrchopliketherapy AT nishimuran highpretreatmentlevelofsolubleinterleukin2receptorisarobustprognosticfactorinpatientswithfollicularlymphomatreatedwithrchopliketherapy AT mishimay highpretreatmentlevelofsolubleinterleukin2receptorisarobustprognosticfactorinpatientswithfollicularlymphomatreatedwithrchopliketherapy AT takeuchik highpretreatmentlevelofsolubleinterleukin2receptorisarobustprognosticfactorinpatientswithfollicularlymphomatreatedwithrchopliketherapy AT hatakek highpretreatmentlevelofsolubleinterleukin2receptorisarobustprognosticfactorinpatientswithfollicularlymphomatreatedwithrchopliketherapy |